{"disease":{"id":"resectable-hepatocellular-carcinoma-with-high-risk-of-recurrence","name":"resectable hepatocellular carcinoma with high risk of recurrence"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07064681","title":"The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07239245","title":"Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT06954116","title":"Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":26,"lead_sponsor_name":"Tongji Hospital","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}